Treatment of Enterococcus Faecalis Bacterem
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Enterococcus Faecalis Bacteremia. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Impact on Mortality of the Choice Between a Mono- Versus Combination Antibiotic Therapy in Enterococcus Faecalis Bacteremia
Overview
Enterococcus faecalis is a germ frequently responsible for bacteremia which can be severe with 15-25% risk of mortality and 26% risk of infectious endocarditis. There is no recommendation for the treatment of "simple" Enterococcus faecalis bacteremia (meaning without infectious endocarditis at diagnosis), nor studies comparing monotherapy versus combination antibiotic therapy. Our main objective is to study the impact on mortality of bacteriostatic monotherapy and bactericidal combination antibiotic therapy in patients with Enterococcus faecalis bacteremia. We aim to also study the mortality up to three months, the failures of treatment, the modalities of treatment, the renal toxicity and the bacterial resistance.
Primary outcome measures
- Intrahospital all-cause mortality [Time frame: Up to 6 months]
Eligibility criteria
Inclusion criteria
- Subject of legal age (≥18 years)
- Having a positive blood culture result for Enterococcus faecalis identified within the microbiology laboratory of the University Hospital of Strasbourg during the period from 01 January 2017 to 31 December 2023.
Exclusion criteria
- Penicillin treatment < 7 days
- Treatment not containing a penicillin effective against enterococci among those studied: amoxicillin or piperacillin-tazobactam
- Combination of penicillin with another antibiotic effective against enterococci other than cephalosporins or aminoglycosides (glycopeptides, linezolids, carbapenems, levofloxacin, moxifloxacin).
- Bacteremia with one or more other pathogens within the first 7 days of bacteremia
- Infective endocarditis at diagnosis and within the first 7 effective days of treatment
- Resistance of Enterococcus faecalis to amoxicillin
- Mortality <72 hours after initiation of antibiotic therapy
- Lack of information regarding the chosen antibiotic treatment
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Case-control
Study locations
France · 1 center
- Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France — Strasbourg
Identifiers
NCT: NCT07299539 · 9378